Indirect Wellbutrin Buyers Denied Cert. Against GSK
GlaxoSmithKline PLC has escaped a class suit from indirect purchasers of Wellbutrin SR who say the company initiated sham patent litigation to avoid competition, convincing a federal judge the plaintiffs would...To view the full article, register now.
Already a subscriber? Click here to view full article